RUCDR Infinite Biologics awarded $6 million grant from NINDS

The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a five-year grant worth up to $6,034,323 to RUCDR Infinite Biologics, a unit of Rutgers' Human Genetics Institute of New Jersey. RUCDR, which is located on Rutgers' Busch Campus in Piscataway, is the world's largest university-based biorepository.

With the new grant, the Rutgers operation will take over management of the NINDS stem cell repository. RUCDR also will provide a comprehensive range of stem-cell related services including derivation and quality control of induced Pluripotent Stem Cells (iPSCs), to researchers throughout the world investigating diseases including Parkinson's, amyotrophic lateral sclerosis (ALS), and Huntington's. These scientists will therefore have greater access to high quality stem cells and other biospecimens that is essential to their work, according to Jay Tischfield, CEO and founder of RUCDR Infinite Biologics and the Duncan and Nancy Macmillan Distinguished Professor of Genetics at Rutgers.

"Under this new grant from NINDS, we will be utilizing innovative technologies, including molecular characterization of stem cell pluripotency and genomic stability, to provide the highest quality cell lines and data to advance discovery in areas of focus for NINDS," Tischfield said. "We also will use cutting-edge methods such as CRISPR-based systems to edit the genomes of induced pluripotent stem cells, generating powerful tools for research into the genetic causes and correlates of nervous system disorders."

RUCDR has been providing genomic services to NIH-funded researchers since 1998 and stem cell services since 2011, including management of the National Institute of Mental Health (NIMH) Stem Cell Center and the iPSC collection of the NIH Center for Regenerative Medicine.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI model developed by SOPHiA GENETICS and UroCCR predicts post-operative outcomes in kidney cancer study